Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Blocking Free Radicals To Prevent Age-Related Disease

XTALKS VITALS NEWS

Cell Culture

Despite being a normal part of cellular energetics, free radicals can cause damage to other parts of the cell, and seem to accumulate more in association with cellular stress, disease and aging.

Tweetables from this article:

Tweet: #Clinicaltrials of #antioxidants have failed to provide compelling evidence for free radical-fighting benefits http://ctt.ec/4ibNJ+ Clinical trials of antioxidants have failed to provide compelling evidence for free radical-fighting benefits.

Share this!

October 6, 2016 | by Sarah Hand, M.Sc.

Free radicals cause cellular damage, which has been implicated in many diseases associated with aging, however few truly effective treatments exist to prevent free radicals wreaking havoc on our bodies. While food and nutritional supplements often tout the benefits of antioxidants at combating free radicals, most clinical trials have failed to provide compelling evidence supporting these claims.

According to Dr. Martin Brand, a researcher at the Buck Institute for Research on Aging, in Novato, California, current free radical-fighting treatments may be too broad to have a significant impact on the reactive cellular components. “Rather than a sledgehammer that seeks to decrease the effects of free radicals, we’ve developed a scalpel that allows us to stop them from being produced in the first place,” said Brand.

The generation of free radicals occurs within the energy-producing organelles in the cell, the mitochondria. Despite being a normal part of cellular energetics, free radicals can cause damage to other parts of the cell, and seem to accumulate more in association with cellular stress, disease and aging.

As the generation of free radicals is intimately connected to the cell’s essential production of energy, the challenge for researchers has been to develop drugs that block free radical release without interfering with energy metabolism. In their search for a targeted drug capable of performing this function, Brand and his colleagues screened a library of 635,000 small molecules.



They identified a few small molecules which were targeted toward a specific site in the electron transport chain, thought to be a key producer of free radicals. The research was published in the journal, Cell Metabolism.

The researchers tested these small molecule drug candidates in cell culture, isolated hearts and living disease models. In a mouse heart model of ischemia, the compounds were able to protect the cells against reperfusion injury when the blood supply was returned to the oxygen-deprived organ.

“For the first time we can test the effects of free radical damage in Alzheimer’s, Parkinson’s, cancer, type 2 diabetes, macular degeneration – you name it,” said Brand. “It gives you a target, and a drug candidate to hit that target.

“We can start to answer questions that scientists have puzzled about for 50 years in terms of the specifics of oxidative damage. We now have a precise tool to find out if the theory is correct. We can go into a biological system, see specifically what free radicals do and take preliminary steps to stop it.”


Keywords: Cellular Damage, Age-Related Disease, Small Molecule Drug


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.